A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts

References

• European Medicines Agency. Summary of product characteristics. Imraldi 40 mg solution for injection in pre-filled syringe; 2021 [cited 2021 Jul 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/imraldi-epar-product-information_en.pdf
   Google Scholar
• Samsung Bioepis. Highlights of prescribing information. Hadlima (adalimumab-bwwd) injection, for subcutaneous use); 2021 [cited 2021 Jul 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761059s000lbl.pdf
   Google Scholar
• Argollo M, Fiorino G, Gilardi D, et al. Biosimilars of adalimumab in inflammatory bowel disease: are we ready for that? Curr Pharm Des. 2019;25(1):7–12.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for the Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products; 2020 [cited 2020 Nov 9]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf
   Google Scholar
• US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry; 2021 [cited 2021 Jul 20]. Available from: https://www.fda.gov/media/82647/download
   Google Scholar
• Lee JJ, Yang J, Lee C, et al. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®. Biologicals. 2019;58:7–15.
   PubMed Web of Science ®Google Scholar
• Lee N, Lee JJ, Yang H, et al. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs. 2019;11(1):129–144.
   PubMed Web of Science ®Google Scholar
• Shin D, Lee Y, Kim H, et al. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42(6):672–678.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):40–48.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics. Humira 20 mg solution for injection in pre-filled syringe; 2021 [cited 2021 Jul 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
   Google Scholar
• Abbot Laboratories. Highlights of prescribing information. Humira (adalimumab) injection, solution for subcutaneous use; 2021 [cited 2021 Jul 20]. Available from: https://www.rxabbvie.com/pdf/humira.pdf
   Google Scholar
• Lukas M, Malickova K, Kolar M, et al. Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical centre. J Crohns Colitis. 2020;14(7):915–919.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) guide on methodological standards in pharmacoepidemiology (revision 8). Available from: http://www.encepp.eu/standards_and_guidances/documents/GuideMethodRev8.pdf
   Google Scholar
• Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques; 2021 [cited 2021 Jul 20]. Available from: https://support.sas.com/resources/papers/proceedings/proceedings/sugi26/p214-26.pdf
   Google Scholar
• Di Cesare A, Tronconi G, Fastame TM, et al. SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2020;33:e13435.
   PubMed Web of Science ®Google Scholar
• Dragoni G, Pieraccini A, Bagnoli S, et al. Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: real-life experience of a tertiary referral centre. Presented at: European Crohn's and Colitis Organisation (ECCO); 2020. Virtual.
   Google Scholar
• Padilla Suarez C, Webb K, Persad N, et al. Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD. Presented at: European Crohn's and Colitis Organisation (ECCO); 2020. Virtual.
   Google Scholar
• Young D, Freudensprung U, Harris C, et al. IBD reference and biosimilar adalimumab CroSS over study (iBaSS): design considerations and methodology. Presented at: European Crohn's and Colitis Organisation (ECCO); 2020. Virtual.
   Google Scholar
• Rosembert D, Malaviya A, How J, et al. Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience. Presented at: European Crohn's and Colitis Organisation (ECCO); 2020. Virtual.
   Google Scholar
• Müller-Ladner U, Gaffney K, Jadon D, et al. The PROPER study: results of the first interim analysis of a pan-EU real-world study of SB5 biosimilar following transition from reference adalimumab in patients with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis. Arthritis Rheumatol. 2020;72(suppl 10):Abstract 0805.
   Google Scholar
• Dignass AU, Gisbert JP, Freudensprung U, et al. The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease. Presented at: European Crohn's and Colitis Organisation (ECCO); 2021. Virtual.
   Google Scholar
• Tapete G, Bertani L, Pieraccini A, et al. Effectiveness and safety of nonmedical switch from adalimumab originator to SB5 biosimilar in patients with inflammatory bowel diseases: twelve-month follow-up from the TABLET registry. Inflamm Bowel Dis. 2022;28(1):62–69.
   PubMed Web of Science ®Google Scholar
• Pouillon L, Danese S, Hart A, et al. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Aliment Pharmacol Ther. 2019;49(9):1181–1187.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Pouillon L, Argollo M, et al. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: results of a workshop from the NOCE-BIO consensus group. Dig Liver Dis. 2020;52(2):138–142.
   PubMedGoogle Scholar